Compare MRDN & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRDN | MDWD |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.1M | 181.1M |
| IPO Year | 2008 | 2013 |
| Metric | MRDN | MDWD |
|---|---|---|
| Price | $11.30 | $12.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $19.73 | ★ $30.67 |
| AVG Volume (30 Days) | 50.1K | ★ 81.0K |
| Earning Date | 10-29-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $182,863,373.00 | N/A |
| Revenue This Year | $12.08 | $39.60 |
| Revenue Next Year | $10.93 | $34.34 |
| P/E Ratio | $31.74 | ★ N/A |
| Revenue Growth | ★ 21.01 | N/A |
| 52 Week Low | $6.01 | $12.52 |
| 52 Week High | $16.09 | $20.03 |
| Indicator | MRDN | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 28.89 | 38.86 |
| Support Level | $9.99 | $12.52 |
| Resistance Level | $14.76 | $14.06 |
| Average True Range (ATR) | 0.58 | 0.38 |
| MACD | -0.25 | -0.06 |
| Stochastic Oscillator | 7.32 | 5.13 |
Meridian Holdings Inc is engaged in the online gaming and betting business, providing sports betting, online casino, and gaming operations across multiple jurisdictions in Europe, Africa, and Central and South America. The company has three reportable segments: MeridianBet Group, GMAG, and RKings & CFAC. The MeridianBet Group segment includes retail and online sports betting, casinos, and related gaming operations. The GMAG segment focuses on the resale of third-party gaming content, mainly serving customers in the Asia-Pacific region. The RKings & CFAC segment is involved in pay-to-enter prize competitions and trade promotions conducted in the United Kingdom and Australia. It generates the majority of its revenue from the MeridianBet Group segment.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.